Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer.
Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.
Chambers
S K
SK
Department of Hematology, Yale University School of Medicine, New Haven, Connecticut 06510.
Chopyk
R L
RL
Chambers
J T
JT
Schwartz
P E
PE
Duffy
T P
TP
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000188:drug therapy; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011289:Preleukemia / Q000139:chemically induced*; D013577:Syndrome
D004317:Doxorubicin; D002945:Cisplatin